Kadimastem Ltd - Asset Resilience Ratio
Kadimastem Ltd (KDST) has an Asset Resilience Ratio of 16.66% as of September 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check KDST strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2015)
This chart shows how Kadimastem Ltd's Asset Resilience Ratio has changed over time. See KDST equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Kadimastem Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Kadimastem Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA1.20 Million | 16.66% |
| Total Liquid Assets | ILA1.20 Million | 16.66% |
Asset Resilience Insights
- Good Liquidity Position: Kadimastem Ltd maintains a healthy 16.66% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kadimastem Ltd Industry Peers by Asset Resilience Ratio
Compare Kadimastem Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
ABL Bio Inc
KQ:298380 |
Biotechnology | 1.05% |
|
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP |
Biotechnology | 80.13% |
|
Ascletis Pharma Inc
F:2VJ |
Biotechnology | 22.13% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 29.87% |
Annual Asset Resilience Ratio for Kadimastem Ltd (2013–2015)
The table below shows the annual Asset Resilience Ratio data for Kadimastem Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2015-12-31 | 31.57% | ILA2.50 Million ≈ $6.70K |
ILA7.92 Million ≈ $21.23K |
-24.87pp |
| 2014-12-31 | 56.45% | ILA6.79 Million ≈ $18.20K |
ILA12.02 Million ≈ $32.24K |
+0.90pp |
| 2013-12-31 | 55.55% | ILA6.89 Million ≈ $18.48K |
ILA12.41 Million ≈ $33.27K |
-- |
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more